MolMiner: Toward Controllable, Three‐Dimensional‐Aware, Fragment‐Based Molecular Design
Advanced Intelligent Discovery · 06.07.2026
DOI: 10.1002/aidi.70138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Intelligent Discovery, online erschienen am 06.07.2026. Verfasst von Raul Ortega‐Ochoa und 2 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We introduce MolMiner, a fragment‐based, geometry‐aware, and order‐agnostic autoregressive model for molecular design. MolMiner supports high‐dimensional conditional control over 12 physicochemical and structural properties from partial specifications, constructs molecules via symmetry‐aware fragment attachments, and conditions each generation step on force‐field‐relaxed three‐dimensional geometry of the partial structure. Conditional control emerges without auxiliary property losses. On targeted property windows, conditioning lifts hit rates by up to 5.25 over unconditional generation and 3.5 over the training distribution itself—overriding the model's intrinsic biases—at the cost of a small reduction in unconditional distributional fidelity. MolMiner unifies dynamic geometry, symmetry handling, order‐agnostic generation, and scalable multi‐property conditioning within a single framework.
Zitieren
APA
Ortega‐Ochoa, R., Vegge, T., & Frellsen, J. (2026). MolMiner: Toward Controllable, Three‐Dimensional‐Aware, Fragment‐Based Molecular Design. Advanced Intelligent Discovery. https://doi.org/10.1002/aidi.70138
Vancouver
Ortega‐Ochoa R, Vegge T, Frellsen J. MolMiner: Toward Controllable, Three‐Dimensional‐Aware, Fragment‐Based Molecular Design. Advanced Intelligent Discovery. 2026. doi:10.1002/aidi.70138
BibTeX
@article{OrtegaOchoa2026,
author = {Ortega‐Ochoa, Raul and Vegge, Tejs and Frellsen, Jes},
title = {MolMiner: Toward Controllable, Three‐Dimensional‐Aware, Fragment‐Based Molecular Design},
journal = {Advanced Intelligent Discovery},
year = {2026},
doi = {10.1002/aidi.70138}
}
EUVIMED